Tag Archives: BIO CEO & Investor Conference

BIO CEO & Investor Conference Kicks Off in NYC

CEO2013_115x75_Thumbnail copy

The 17th Annual BIO CEO & Investor Conference opened today with a record number of partnering meetings and company presentations, in addition to key policy, business, and science panels highlighting the biotech issues of the day. During the Welcome & Opening Plenary session, BIO President & CEO Jim Greenwood spoke with Energy & Commerce Committee Chairman Fred Upton (R-MI) and Congresswoman Diana DeGette (D-CO) about the 21st Century Cures Initiative, a comprehensive effort to accelerate the discovery, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Getting Ahead of Ebola and Other Infectious Threats—Overturning Assumptions


Ebola was one of the biggest stories of 2014 (with Ebola fighters named the TIME Person of the Year), and the epidemic has led to renewed interest from governments and philanthropies to tackle the problem of emerging infectious diseases. To discuss the lessons learned and new approaches being taken in light of the Ebola crisis, BIO hosted a panel today at the 17th Annual BIO CEO & Investor Conference here in New York, moderated by Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

How Industry Rates Interactions with the FDA


Kicking off day one of the BIO CEO & Investor Conference in New York City, panelists in the ‘How Industry Rates Interactions with the FDA’ session brought attendees good news – communication with the FDA has improved overall. “The improvements we have seen in increased communications between FDA and sponsors is based on a continuous dialogue that has been established over the past several years in which BIO has been at the forefront,” said Jonathan Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Patients Remain the Focus for the Future of Personalizing Oncology


The 17th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria in New York City, kicked off this morning with an interactive panel of industry heavyweights discussing the growing trend to personalize oncology treatments with molecular diagnostics. Moderated by Michael King, Managing Director, Senior Research Analyst, JMP Securities. Michael helped steer the group of experts as they discussed enabling broader matching of patient-cancer-therapy, lessons learned from the Cancer Genome Atlas and the potential Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Dow Jones VentureWire: BIO Report on Venture Funding for Therapeutic Innovation


Today, Brian Gormley’s story – Biotech VCs Shift Away From Chronic Diseases, Report Says – highlights VC funding trends over a 10-year period. BIO released the report today showing that venture capital is shifting away from chronic diseases and increasing for rare diseases. The report categorized $38 billion of investment across more than 1,200 companies from 2004 through 2013. BIO’s report compares five-year periods before and after the financial crisis. From 2004 through 2008, for Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,